Biogen: redeployment of resources in Alzheimer's disease
On the other hand, the Group will terminate the development and commercialization of Aduhelm 100 mg/mL injectable for intravenous use, as well as the Envision clinical trial, a decision that is not related to safety or efficacy issues.
Biogen has recorded a non-recurring charge of approximately $60 million related to the costs of closing this program in the fourth quarter of 2023. A large part of the resources thus freed up will be redeployed in its AD franchise.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction